{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neulasta%C2%AE+%28pegfilgrastim%29&page=2", "query": { "intervention": "Neulasta® (pegfilgrastim)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neulasta%C2%AE+%28pegfilgrastim%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neulasta%C2%AE+%28pegfilgrastim%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T09:49:11.744Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02953340", "title": "SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neutropenia", "Breast Cancer" ], "interventions": [ { "name": "SPI-2012", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2017-05-10", "completion_date": "2019-05-06", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 49, "location_summary": "Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953340" }, { "nct_id": "NCT01712009", "title": "NOLAN: Naproxen or Loratadine and Neulasta", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Pain in Stage I - III Breast Cancer" ], "interventions": [ { "name": "Naproxen", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 600, "start_date": "2012-11-01", "completion_date": "2015-03-18", "has_results": true, "last_update_posted_date": "2018-01-30", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 83, "location_summary": "Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712009" }, { "nct_id": "NCT03206229", "title": "Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "PEG-rhG-CSF", "type": "DRUG" }, { "name": "Neulasta (PEG-rhG-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adello Biologics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 120, "start_date": "2017-02-13", "completion_date": "2018-01-18", "has_results": false, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206229" }, { "nct_id": "NCT00911170", "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Colon Cancer", "Colorectal Cancer", "Fever", "Locally Advanced", "Metastatic Colorectal Cancer", "Neutropenia", "Rectal Cancer" ], "interventions": [ { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 847, "start_date": "2009-11-03", "completion_date": "2015-01-02", "has_results": true, "last_update_posted_date": "2017-12-29", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 72, "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911170" }, { "nct_id": "NCT02469116", "title": "Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pegylated G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2006-01", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2016-08-19", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469116" }, { "nct_id": "NCT02098109", "title": "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "XM02 Filgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2014-08-20", "completion_date": "2016-09-18", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098109" }, { "nct_id": "NCT02418104", "title": "Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Immunity, Humoral" ], "interventions": [ { "name": "CHS-1701", "type": "DRUG" }, { "name": "Pegfilgrastim (Neulasta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 303, "start_date": "2015-05", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 4, "location_summary": "Overland Park, Kansas • Cincinnati, Ohio • San Antonio, Texas + 1 more", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418104" }, { "nct_id": "NCT02181218", "title": "Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Cutaneous", "Lymphoma, T-Cell, Peripheral", "Hodgkin Disease", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-02-04", "completion_date": "2020-06-26", "has_results": false, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 2, "location_summary": "Chicago, Illinois • St Louis, Missouri", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02181218" }, { "nct_id": "NCT06528691", "title": "Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "CNS Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Years", "sex": "ALL", "summary": "Up to 3 Years" }, "enrollment_count": 52, "start_date": "2026-05-01", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528691" }, { "nct_id": "NCT01648322", "title": "Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Neutropenia" ], "interventions": [ { "name": "F-627", "type": "DRUG" }, { "name": "Neulasta® (pegfilgrastim)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EVIVE Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "18 Years to 74 Years · Female only" }, "enrollment_count": 232, "start_date": "2012-06", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-07T09:49:11.744Z", "location_count": 1, "location_summary": "Anderson, Indiana", "locations": [ { "city": "Anderson", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01648322" } ] }